Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 44351 - 44375 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Fulvestrant	Approved Investigational	CENPA	1058	downregulated	fulvestrant results in decreased expression of CENPA mRNA	2p23.3	A20479
Fulvestrant	Approved Investigational	CLK1	1195	upregulated	fulvestrant results in increased expression of CLK1 mRNA	2q33.1	A20482
Fulvestrant	Approved Investigational	CLMN	79789	upregulated	fulvestrant results in increased expression of CLMN mRNA	14q32.13	A21106
Fulvestrant	Approved Investigational	CLSTN1	22883	downregulated	fulvestrant results in decreased expression of CLSTN1 mRNA	1p36.22	A20479
Fulvestrant	Approved Investigational	CNBP	7555	upregulated	fulvestrant results in increased expression of CNBP mRNA	3q21.3	A20482
Fulvestrant	Approved Investigational	COPB2	9276	downregulated	fulvestrant results in decreased expression of COPB2 mRNA	3q23	A20479
Fulvestrant	Approved Investigational	CSF1	1435	upregulated	fulvestrant results in increased expression of CSF1 mRNA	1p13.3	A20482
Fulvestrant	Approved Investigational	CSF3	1440	downregulated	fulvestrant results in decreased expression of CSF3 mRNA	17q21.1	A21168
Fulvestrant	Approved Investigational	CSTA	1475	downregulated	fulvestrant results in decreased expression of CSTA mRNA	3q21.1	A21102
Fulvestrant	Approved Investigational	CTSD	1509	downregulated	fulvestrant results in decreased expression of CTSD mRNA	11p15.5	A22733
Fulvestrant	Approved Investigational	CTSD	1509	upregulated	fulvestrant results in increased expression of CTSD mRNA	11p15.5	A21102
Fulvestrant	Approved Investigational	CTSH	1512	upregulated	fulvestrant results in increased expression of CTSH mRNA	15q25.1	A20479
Fulvestrant	Approved Investigational	CXCL12	6387	downregulated	fulvestrant results in decreased expression of CXCL12 mRNA	10q11.21	A21106
Fulvestrant	Approved Investigational	CXCL3	2921	upregulated	fulvestrant results in increased expression of CXCL3 mRNA	4q13.3	A21168
Fulvestrant	Approved Investigational	CXCL8	3576	upregulated	fulvestrant results in increased expression of CXCL8 mRNA	4q13.3	A21168
Fulvestrant	Approved Investigational	CYCS	54205	upregulated	fulvestrant results in increased expression of CYCS mRNA	7p15.3	A21141
Fulvestrant	Approved Investigational	CYP1A1	1543	upregulated	[fulvestrant results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA	15q24.1	A20478
Fulvestrant	Approved Investigational	CYP1A1	1543	upregulated	fulvestrant results in increased expression of CYP1A1 mRNA	15q24.1	A20478
Fulvestrant	Approved Investigational	DDX21	9188	downregulated	fulvestrant results in decreased expression of DDX21 mRNA	10q22.1	A20479
Fulvestrant	Approved Investigational	DDX3Y	8653	downregulated	fulvestrant results in decreased expression of DDX3Y mRNA	Yq11.221	A20479
Fulvestrant	Approved Investigational	DHX9	1660	downregulated	fulvestrant results in decreased expression of DHX9 mRNA	1q25.3	A20479
Fulvestrant	Approved Investigational	DLEU2	8847	upregulated	fulvestrant results in increased expression of DLEU2 mRNA	13q14.2	A21102
Fulvestrant	Approved Investigational	DMBT1	1755	upregulated	fulvestrant results in increased expression of DMBT1 mRNA	10q26.13	A22734
Fulvestrant	Approved Investigational	DNAJA1	3301	downregulated	fulvestrant results in decreased expression of DNAJA1 mRNA	9p21.1	A20479
Fulvestrant	Approved Investigational	DNMT1	1786	downregulated	fulvestrant results in decreased expression of DNMT1 mRNA	19p13.2	A22729

Displaying entries 44351 - 44375 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability